Grant funding delivered in partnership with the NC3Rs, in support of UK Government roadmap to reduce animal testing by 2030 Project to develop standardized workflow to more accurately predict drug behaviors, reduce animal testing and streamline development of safer, more effective medicines   Cambridge, UK, 12 August 2026: CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced it has been awarded £180k grant funding from Innovate UK. Delivered in partnership with the National Centre for…

A new funded programme will support start-ups applying structural chemistry data, AI and machine learning to solve real-world scientific challenges The Cambridge Crystallographic Data Centre (CCDC) today announced the launch of the CCDC Innovation Fund, a new seed funding programme designed to support emerging companies developing innovative solutions in structural chemistry. The fund, backed by an initial commitment from the CCDC of up to £300,000, will provide early-stage support to start-ups and university spin-outs seeking to transform structural chemistry research into impactful…

As life sciences businesses balance growth ambitions with tighter budgets, the value of industry events is under increasing scrutiny. Organisations still need to connect with customers, collaborators and peers, but they also need confidence that each event delivers a clear return for the time and money invested.We asked CEO Geoff Davison to explain why Bionow's events programme continues to grow across the North of the UK, with more than 35 events delivered to over 2,500 attendees in 2025. He discusses how the programme delivers exceptional value compared with many larger conferences, and why…

·        Extension of the INDUCE-seq platform to support adenine base editing (ABE) workflows ·        Researchers invited to gain early access to platform and support ongoing product development Cambridge, UK, 10 August 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the launch of BaseMap™ ABE. Built on the Company's INDUCE-seq® technology, BaseMap ABE extends the platform's capabilities to…

Eramol is progressing the development of its purpose-built sterile fill-finish facility in Sevenoaks, Kent, designed to support Phase I and Phase II injectable clinical-trial programmes with flexible batch sizes, isolator-based aseptic processing with <0.1% line losses and integrated packaging, labelling, QC & UK and EU QP release.Sevenoaks, UK: Eramol is advancing the development of its new sterile fill-finish facility in Sevenoaks, strengthening UK capacity for early-phase injectable clinical-trial manufacturing.Scheduled to become fully operational in Q3/Q4 2026, the purpose-built…

EY UK DNA of the CFO - Key findings UK CFOs are being asked to play a bigger role in how organisations create value. As AI reshapes business models, accelerates change and transforms the nature of work, finance is increasingly expected not only to measure performance, but to help shape it. The next evolution of finance is not about producing more insight. It is about turning ambition into value.Yet ambition alone is not enough. While 81% of UK CFOs expect AI-enabled business models, only 8% say AI is fully integrated across finance operations. The challenge is no longer recognising the…

Global IPO markets are progressing on different trajectories. Prepared companies that maintain timing flexibility are positioned to win. In brief IPO markets are gaining momentum, with strong 1H activity setting the stage for what could be a historic 2H 2026. Markets are strong, but execution windows may be episodic and could be shaped by mega-IPOs and geopolitics. Companies pursuing public listings are using more flexible approaches — IPOs, direct listings and SPACs — to capitalize on improving market conditions.

Stevenage, UK, 3 August 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026. A recognized leader in neuroscience drug development with particular expertise in ALS, Dr Sundgreen brings over 25 years of clinical leadership with experience spanning translational medicine and all phases of clinical development from first-in-human studies…

Round led by Molten Ventures alongside existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension Investment will support Qureight’s next-generation AI-powered quantitative imaging platform to further accelerate clinical trials in lung fibrosis Building a state of the art AI imaging laboratory will allow Qureight to move rapidly into new lung and heart diseases including asthma, pulmonary hypertension and bronchiectasis Cambridge, UK, 29 July 2026 – Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision…

Offers UK academic, biotech and biopharma researchers direct access to specialist project support, 10x Genomics Chromium Single Cell-based workflows, sequencing infrastructure and bioinformatics expertise Cambridge, UK, 27 July 2026: Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre. This expansion brings single-cell sequencing workflows built around the 10x Genomics Chromium platform closer to academic, biotech and biopharma researchers in the UK. The service builds on Novogene…